Gilde Healthcare co-led the round, which was also backed by other existing investors Cipio Partners and TVM Capital also participated in the round.
Wellington made the investment from its Partners IV Life Science Fund, which was closed last September.
Definiens said the funds will enable it to grow its global business in digital pathology image analysis and expand into digital tissue diagnostics.
Wellington general partner Rainer Strohmenger said, “We have been following Definiens for many years and have always been impressed by the visionary concept and exciting technology the company has.
“We believe that Definiens now is approaching an inflection point which will have a significant impact on the growth potential and strategic value of this business for the leading players in imaging, diagnostics and oncology drug development.”
Definiens raised a €10m round led by Gilde in October 2012.
Copyright © 2014 AltAssets